Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Notebook: Clinical Trial Fatality; Affordable Medicines Debate; Physician Payment Disclosure

Executive Summary

One death and five healthy volunteers hospitalized in a Phase I study in France; EU Council looks set to debate patient access to medicines; and the two Mercks set to continue litigation in Europe and the US over use of the Merck word, straining their 60-year-old agreement. Generics/biosimilar trade group adopts physician payment disclosure policy.

You may also be interested in...

European Notebook: UK To Leave EU; Prices Attract Political Attention; Advanced Therapies Revamp

Brexit vote creates uncertainty about biopharma policies in the UK and how local companies interact with the rest of the world;; antibiotic use decreases in several countries; high prices prompt European Commission review of industry incentives.

French Probe Possibility Of Manslaughter In Phase I Trial Case

Review will consider whether study fatality and serious injuries were a matter of "scientific chance" or "faults of a criminal nature"; separate evaluations will inform guidelines on first-in-human trials.

European Notebook: All Change In The C-Suites; EMA PRIME Starts; French Experts Recommend Phase I Changes

Once-in-a-decade leadership changes stack up in Europe’s big pharma companies as the region aims for quicker and more certain drug development, although following a recent fatality an expert committee is advising caution during dose-escalation in Phase I studies.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts